Strategic Trust Kelly CRISPR & Gene Editing Technology ETF
XDNA
XDNA was delisted on the 30th of November, 2023.
2 hedge funds and large institutions have $95.8K invested in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$108K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.61K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $92.6K | +$108K | +12,486 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $3.11K | +$3.61K | +419 | New |
|
XDNA Hedge Fund Activity: Q3 2023 in Review
2 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) for Q3 2023, worth a combined $95.8K.
Buyers outnumbered sellers: 2 funds opened new XDNA positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $108K.
- 2 institutional investors held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) as of Q3 2023, up from 0 in Q2 2023.
- Funds reported $95.8K of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF stock for Q3 2023.
- 2 funds opened new Strategic Trust Kelly CRISPR & Gene Editing Technology ETF positions in Q3 2023 and 0 closed out, a net change of +2 holders.
- The largest Strategic Trust Kelly CRISPR & Gene Editing Technology ETF buyer in Q3 2023 was Jane Street, an estimated $108K added.
Based on aggregated 13F filings for Q3 2023.